Nirmatrelvir/Ritonavir

According to an analysis by 3 Axis Advisors, American pharmaceutical companies plan to raise the prices of at least 250 brand-name drugs in early 2025. These drugs include Pfizer's COVID-19 treatment Paxlovid, Bristol Myers Squibb's cancer treatment drugs, and Sanofi's vaccines. While most drug price increases are below 10%, the median increase on January 1 is 4.5%, consistent with last year. Pharmaceutical companies have reduced the extent of price increases in recent years after facing criticism for significant price hikes over the past decade. Notably, the price increase figures do not include rebates and other discounts from pharmacy benefit managers. In the US, substantial price increases for drugs used to be more common, but pharmaceutical companies have reduced their price hikes in response to public criticism. 3 Axis Advisors' President Antonio Ciaccia noted, "Pharmaceutical companies have limited room to raise prices, meaning their only option is to take greater liberties with the launch prices." A Reuters analysis shows that the prices of new drugs in the US in 2023 were 35% higher than in 2022. Compared to December 29 of last year, over 140 brand-name drugs have announced price hikes, with more than 250 drugs seeing increased price margins. Additionally, pharmaceutical companies will also lower the prices of some drugs on January 1. For example, Merck & Co announced significant reductions in the price of its diabetes drugs Januvia and Janumet to bring their prices closer to the net price. The US has the highest spending on prescription drugs globally, and incoming President Donald Trump promised to lower drug costs by focusing on middlemen in the healthcare system. Other pharmaceutical companies may announce more drug price increases in January, as historically, January has been the month with the highest price hikes. Pfizer has increased the prices of most of its drugs, raising prices on over 60 drugs, including Paxlovid. The company raised the price of Paxlovid by 3%, while several other drugs saw price increases of 3% to 5%. Pfizer spokesperson Amy Rose stated in an email that the company has adjusted the average list prices of drugs and vaccines for 2025 to be below the overall inflation rate, at about 2.4%. She emphasized that this increase helps support investments in drug development and offsets costs. Bristol Myers Squibb raised the prices of its expensive cancer cell therapies Abecma and Breyanzi by 6% and 9%, respectively. A spokesperson for BMS mentioned the company's commitment to ensuring patients can access their drugs easily and noted that the price of Breyanzi reflects its potential transformative personalized treatment. Sanofi increased the prices of several vaccines by 2.9% to 9%. According to 3 Axis's analysis, the brand with the largest increase is Leadiant Pharmaceuticals under Essetifin in Italy. The company raised the price of the drug Matulane, used to treat Hodgkin's disease, by about 15%, and the eye drops Cystaran, used for the rare cystinosis disease, by about 20%. Spokespersons for Leadiant and Sanofi did not immediately respond to requests for comments.

WATERTOWN, Mass.--( BUSINESS WIRE )-- Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District Court of Massachusetts (“the Court”) has issued a ruling on a summary judgment motion filed by Pfizer, Inc. in connection with Enanta’s patent infringement lawsuit seeking damages for infringement of U.S. Patent No. 11,358,953 (“the ’953 Patent”) in the manufacture, use and sale of Pfizer’s COVID-19 antiviral, Paxlovid™ (nirmatrelvir tablets; ritonavir tablets). The Court issued a summary judgment decision granting Pfizer’s motion that the ‘953 Patent is invalid. In its decision, the Court also denied Enanta’s partial motion for summary judgment of infringement as moot in light of its allowance of summary judgment on invalidity. Enanta plans to appeal the decision to the Court of Appeals for the Federal Circuit. "The U.S. patent system and its protection of important innovations have enabled the robust development of new medicines and spurred growth in the biotechnology industry. We are proud of the impact our strong history of drug discovery work with protease inhibitors has had on antiviral treatments and the thousands of patients that have been treated with therapies using our patented inventions,” said Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals, Inc. “We are disappointed with the Court’s ruling. We believe strongly in the merits of our case, and, through the appeal process, we will continue to defend our inventions from unlawful infringement.” Enanta maintains its commitment to avoid attempting to impede the production, sale or distribution of Paxlovid. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information. Forward-Looking Statements This press release contains forward-looking statements, including statements with respect to Enanta’s suit against Pfizer, Inc. in the United States District Court for the District of Massachusetts seeking damages for patent infringement. Statements that are not historical facts are based on management’s current expectations, estimates, forecasts and projections about Enanta’s business and the industry in which it operates and management’s beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: Enanta is competing to develop intellectual property in areas of small-molecule drug development that are highly competitive; issued patents, including the patent at issue in the Pfizer litigation, could be found invalid or unenforceable if challenged in court and could be costly to defend and be a distraction for Enanta’s senior management and scientific personnel; intellectual property litigation may lead to unfavorable publicity that harms Enanta’s reputation and causes the market price of its common stock to decline; and other risk factors described or referred to in “Risk Factors” in Enanta’s Form 10-K for the fiscal year ended September 30, 2024 and other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law.